Dutch-based Xyall secures €6M to help pathologists obtain more reliable molecular diagnostic test results

▤ Summary

Eindhoven-based Xyall BV, a medtech innovator in molecular pathology, announced on Tuesday that it has raised €6M in its Series B round of funding to accelerate the commercialisation of its Tissector High Throughput and Tissector Table Top systems. Molecular diagnostics has enabled clinicians to target treatment that suits a patient’s specific biological status. These diagnostic tests have advanced in PCR and next-generation sequencing technologies. However, selecting tissue and cell samples for molecular diagnostic testing still remains a labour-intensive manual process with a risk of error and cross-contamination.

▦ Linked Companies